Company intelligence / Profile preview

Cambridge Epigenetix

Cambridge, England, United Kingdombiomodal.com ↗

Ownership: Private
Employees: ~50
Development stage: Commercial

Overview

The company has launched commercial kits enabling simultaneous genetic and epigenetic sequencing at single-base resolution. These tools are used for biomarker discovery and early disease detection. Clinical validation for diagnostics continues; no therapeutic clinical trial results reported.

Therapeutic areas: Oncology
Modalities: Diagnostic technology platform (multiomics sequencing)Sequencing technology platform (not a therapeutic modality but a research/diagnostic tool)
Industry: Molecular Diagnostics

Partnerships

Leading biopharma companies for biomarker discovery partnerships

Beyond the preview

Go deeper on Cambridge Epigenetix.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Cambridge Epigenetix.

Explore the full profile